Ipsen appoints Ioana Parsons as General Manager, U.K. & Ireland

LONDON, U.K., 6 March 2024 – Ipsen (Euronext: IPN; ADR: IPSEY) announced today the appointment of Ioana Parsons as General Manager of the company’s U.K. & Ireland affiliate. Ioana joins us from Ipsen Poland, where she has been General Manager for the past three years. As well as becoming U.K. & I General Manager, Ioana will act as Head of Site for Ipsen’s U.K. Global Hub.

Ioana Parsons said: “I am really excited to be back in London. I cannot wait to get started and work with all my colleagues here to deliver on Ipsen’s bold ambitions in driving innovation across oncology, neuroscience, and rare diseases. The U.K. has a complex healthcare landscape and I’m ready to tackle both the opportunities and the challenges we face here, working together with our dedicated healthcare partners in the U.K. and Ireland to ensure the best possible health outcomes for patients. Our passion continues to be about making a real impact on patients’ lives every day and we do this by discovering innovative medicines that truly make a difference.”

Ioana has a wealth of experience working in the Life Sciences industry including local, regional and global roles at major pharmaceutical companies. In addition to this, she has worked as a consultant at McKinsey & Company in London, where she led large scale strategy and commercial transformation projects for a range of global pharmaceutical clients. She holds a BA in Economics and International Business from the Academy of Economic Sciences in Bucharest and an MBA from London Business School.

Ioana succeeds Guy Oliver and is tasked with continuing to drive our rapidly growing commercial presence in the U.K. and Ireland.

The U.K. & Ireland is one of Ipsen’s three Global Hubs. It is pivotal to the growth and success of the company and employs 1000 people across the region.



About Ipsen

We are a global biopharmaceutical company with a focus on bringing transformative medicines to patients in three therapeutic areas: Oncology, Rare Disease and Neuroscience.

Our pipeline is fueled by external innovation and supported by nearly 100 years of development experience and Global Hubs in the U.S., France and the U.K. Our teams in more than 40 countries and our partnerships around the world enable us to bring medicines to patients in more than 80 countries.

Ipsen is listed in Paris (Euronext: IPN) and in the U.S. through a Sponsored Level I American Depositary Receipt program (ADR: IPSEY). For more information, visit ipsen.com.


 Ipsen contacts


External organization media contacts


CRSC-GB-000114 | March 2024


Disclaimers and/or Forward-Looking Statements

The forward-looking statements, objectives and targets contained herein are based on Ipsen’s management strategy, current views and assumptions. Such statements involve known and unknown risks and uncertainties that may cause actual results, performance or events to differ materially from those anticipated herein. All of the above risks could affect Ipsen’s future ability to achieve its financial targets, which were set assuming reasonable macroeconomic conditions based on the information available today. Use of the words ‘believes’, ‘anticipates’ and ‘expects’ and similar expressions are intended to identify forward-looking statements, including Ipsen’s expectations regarding future events, including regulatory filings and determinations. Moreover, the targets described in this document were prepared without taking into account external-growth assumptions and potential future acquisitions, which may alter these parameters. These objectives are based on data and assumptions regarded as reasonable by Ipsen. These targets depend on conditions or facts likely to happen in the future, and not exclusively on historical data. Actual results may depart significantly from these targets given the occurrence of certain risks and uncertainties, notably the fact that a promising medicine in early development phase or clinical trial may end up never being launched on the market or reaching its commercial targets, notably for regulatory or competition reasons. Ipsen must face or might face competition from generic medicine that might translate into a loss of market share. Furthermore, the research and development process involves several stages each of which involves the substantial risk that Ipsen may fail to achieve its objectives and be forced to abandon its efforts with regards to a medicine in which it has invested significant sums. Therefore, Ipsen cannot be certain that favorable results obtained during preclinical trials will be confirmed subsequently during clinical trials, or that the results of clinical trials will be sufficient to demonstrate the safe and effective nature of the medicine concerned. There can be no guarantees a medicine will receive the necessary regulatory approvals or that the medicine will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Other risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and healthcare legislation; global trends toward healthcare cost containment; technological advances, new medicine and patents attained by competitors; challenges inherent in new-medicine development, including obtaining regulatory approval; Ipsen’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of Ipsen’s patents and other protections for innovative medicines; and the exposure to litigation, including patent litigation, and/or regulatory actions. Ipsen also depends on third parties to develop and market some of its medicines which could potentially generate substantial royalties; these partners could behave in such ways which could cause damage to Ipsen’s activities and financial results. Ipsen cannot be certain that its partners will fulfil their obligations. It might be unable to obtain any benefit from those agreements. A default by any of Ipsen’s partners could generate lower revenues than expected. Such situations could have a negative impact on Ipsen’s business, financial position or performance. Ipsen expressly disclaims any obligation or undertaking to update or revise any forward-looking statements, targets or estimates contained in this press release to reflect any change in events, conditions, assumptions or circumstances on which any such statements are based, unless so required by applicable law. Ipsen’s business is subject to the risk factors outlined in its registration documents filed with the French Autorité des Marchés Financiers. The risks and uncertainties set out are not exhaustive and the reader is advised to refer to Ipsen’s latest Universal Registration Document, available on ipsen.com.



© Ipsen Group 2024